Theoretical benefits of mitogen applications for HIV-1 infections

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 3, 1997, Pages 213-222

  Wimer, Bruce M ^a   Morris, Randall E ^b  

^a JBMW Immunotherapeutics   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Adoptive leukocyte therapy; HIV 1 infection; Interleukin 12; Mitogenic lectins; Phytohemagglutinin; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; LECTIN; MITOGENIC AGENT; NELFINAVIR; NUCLEOSIDE ANALOG; PHYTOHEMAGGLUTININ; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOMODULATION; IMMUNOSTIMULATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

EID: 0030743250     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.213     Document Type: Article

References (46)

1. Panteleo G, Graziosi C, Damarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. HIV-1 is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993;362:355-358.
2. Temen HM, Bolognesi DP. Where has HIV-1 been hiding? Nature 1993;363:292-293.
3. Embretson J., Zupancic M, Ribas J L, Burke A, Racz P, Tenner-Racz K, Haase AT. Massive covert infection of helper T lymphocytes and macrophages by HIV-1 during the incubation period of AIDS. Nature 1993;362:359-362.
4. Nowak MA, May RM, Phillips RE, Rowland-Jones S, Lalloo D, McAdam S, Klenerman P, Köppe B, Sigmund K, Bangham CRM, McMichael AJ Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995;375:606-611.
5. Pasnteleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Eng J Med 1993;328:327-235.
6. Fauci AS, Panteleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection: NIH Conference. Ann Intern Med 1996;124:654-663.
7. Wimer BM. Therapeutic activities of PHA-L4 the mitogenic isolectin of phytohemagglutin-in. Molecular Biotherapy 1990;2:74-90.
8. Wimer BM. Potential therapeutic applications of PHA-L4 the mitogenic isolectin of phyto- hemagglutinin. Molecular Biotherapy 1990, 2:196-200.
9. Wimer BM. The ideal biological response modifier. Molecular Biotherapy 1989;1:311-317.
10. Wimer BM. Characteristics of PHA-L4 the mitogenic isolectin of phytohemagglutinin as an ideal biological response modifier. Molecular Biotherapy 1990;2:4-17.
11. Wimer, BM. Therapeutic immunostimulating effects of plant mitogens exemplified by the L4 isolectin of PHA Cancer Biotherapy and Radiopharmaceuticals 1997;12:195-212.
12. Kanellopoulos JM, De Petris S, Leca G, Crumpton MJ. The mitogenic lectin from Phaseolus vulgaris does not recognize the T3 antigen of human T lymphocytes. Eur J Immunol 1985;15:479-486.
13. Robinson WE, Montefiori DC, Mitchell WM. Evidence that mannosyl residues are involved in human immunodeficiency virus type 1 (HIV-1-1) pathogenesis. Aids Res Human Retroviruses 1987;3:265-282.
14. Lifson J, Coutré S, Huang E, Engleman E. Role of envelope glycoprotein carbohydrate in human immunodeficiency virus (HIV-1) infectivity and virus-induced cell fusion. J Exp Med 1986;164:2101-2106.
15. Sugita N, Niimura K, Oguchi Y, Hirose K, Matsunaga K, Oohara M, Muto S, Kakuchi J, Furosho T, Yoshikumi C, Takahashi M. LECTINS AND ANTIRETROVIRAL DRUGS CONTAINING THE LECTINS AS ACTIVE INGREDIENT United States Patent 4,985,543, Jan. 15, 1991.
16. Pryme IF, Pusztai AJ, Bardocz S. A diet containing the lectin phytohaemagglutinin (PHA) slows down the proliferation of Krebs II cell tumours in mice. Cancer Lett 1994;76.133-137.
17. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: Functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor Science 1996;272:872-877.
18. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goerdert JJ, Bushbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study, OBrien SJ. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science 1996;273:1856-1862.
19. Hauptman SP, Batuman O, Friedman L, Balaban D, Allen-Hagen B, Ifft N, Shapiro SS. Amelioration of immunologic deficits and clinical manifestations of the acquired immunodeficiency syndrome (AIDS) by allogeneic lymphocyte transfusions. Blood 1985;66 Suppl 1 p 113a.
20. Fauci AS. Multifactorial nature of huma deficiency virus disease: Implications for therapy. Science 1993,262:1011-1018.
21. Mazumder A, Grimm EA, Rosenberg SA. Characterization of the lysis of fresh human solid tumors by autologous lymphocytes activated in vitro with phytohemagglutinin. J Immunol 1983;130 958-964.
22. 1995 Survey of New Medicines in Development for AIDS, Introduction and Summary, Pharmaceutical Research and Manufacturers of America. See Ref. 28.
23. Hirsch MS, Daquila RT. Therapy for human immunodeficiency virus infection. N Engl J Med 1993; 328:1686-1695.
24. Johnston MI, Hoth DF. Present status and future prospects for HIV therapies. Science 1993; 260:1286-1293.
25. Erice A, Balfour HH Jr. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin Infect Dis 1994;18:149-156.
26. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
27. Wei X, Gosh SK, Taylor ME, Johnson VA, Emini EA, Deutch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122
28. 1995 Survey of New Medicines in Development for AIDS, Antivirals, Pharmaceutical Research and Manufacturers of America, Novembers, 1995 Copy obtainable from Editor, "New Medicines in Development," Communications Division, Pharmaceutical Research and Manufacturers of America, 1100 15th Street NW, Washington, DC 20005.
29. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Tnnchieri G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exper Med 1989;170:827-845.
30. Stem AS, Podlaski FJ, Hulmes JD, Pan Y-C E, Quinn PM, Wolitzky AG, Familletti PC, Stremlo DL, Truitt T, Chizzonite R, Gately MK. Purification to homogeneity and partial characterization of cytotoxic maturation factor from human B-lymphoblastoid cells. Proc Natl Acad Sci USA 1990;87:6808-6812.
31. Gubler U, Chua AO, Schoenhaut DS, Dwyer CM, McComas W, Motyka R, Nabavi N, Wolitzky AG, Quinn PM, Familletti PC, Gately MK. Coexpression of two distinct genes is required to generate secreted bioactive cytotoxic lymphocyte maturation factor. Proc Natl Acad Sci USA 1991;88:4143-4147.
32. Gately MK, Desai BB, Wolitsky AG, Quinn PM, Dwyer CM, Podlaski FJ, Familletti PC, Sinigaglia F, Chizzonite R, Gubler U, Stern AS. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12, (cytotoxic lymphocyte maturation factor). J Immunol 1991;147:874-882.
33. Wolf SF, Temple PA, Kobayashi M, Young D, Dicig M, Lowe L, Dzialo R, Fitz L, Ferenz C, Hewick RM, Kelleher K, Hermann SH, Clark SC, Azzoni L, Chan SH, Trinchieri G, Perussia B. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J Immunol 1991;146:3074-3081.
34. Trinchieri G. Review: Interleukin 12: A cytokine produced by antigen-producing cells with immuno-regulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84:4008-4027.
35. Clerici M, Shearer GM. A TH1->TH2 is a critical step in the etiology of HIV infection. Immunol Today 1993;14:107-111.
36. Clerici M, Hakim FT, Venzon DJ, Blatt S, Hendrix CW, Wynn TA, Shearer GM Changes in interleukin-2 and interleukin-4 production in asymptomatic human immunodeficiency virus-seropositive individuals. J Clin Invest 1993,91:759-765.
37. Clerici M, Lucey DR, Berzofsky JA, Pinto LA, Wynn TA, Blatt SP, Dolan MJ, Hendrix CW, Wolf SF, Shearer GM. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-1724.
38. H2 predominance in HIV-infected individuals. Science 1994;265:248-252.
39. Hoffman LM. METHOD AND COMPOSITION FOR PRODUCING LECTIN IN MICRO-ORGAN-ISMS. United States Patent 4,870,015 Sept. 26, 1989.
40. Glad C, Borrebaeck CAK Affinity of phytohemagglutinin (PHA) isolectins for serum proteins and regulation of the lectin-induced lymphocyte transformation. J Immunol 1984;133: 2126-2132.
41. Zuckerman KS, LoBuglio AF. Phytohemagglutinin skin tests in cancer patients. Cancer 1977;39: 2355-2361.
42. Wimer BM. Putative effects of mitogenic lectin therapy corroborated by alloactivation data Cancer Biotherapy and Radiophormaceuticals 1996;11:57-75.
43. Morris RE. CONCANAVALIN A DIMERS AS THERAPEUTIC AGENTS. United States Patent 4,889,842 Dec. 26,1989.
44. Busse WW, Swenson CA, Sharpe G, Koschat M. Enhanced basophil histamine release to concanavalin A in allergic rhinitis. J Allergy & Clin Immunol 1986;78:90-97
45. Wimer BM. Haplotype donor-generated graft- versus-leukemia responses: Serendipity revisited. Cancer Biotherapy 1995;10:181-194.
46. Schiavino D, Nucera E, Murzilli F, Schinco G, Papa G, Fais G, Patriarca G Anaphylactic shock after skin test with phytohaemagglutinin. Allergy 1992; 47: 121-122.